MedTrace Logo

Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease

NCT05817799 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2024-08-09

No results posted yet for this study

Summary

OBJECTIVES

* To assess the levels of plasma carnitine in controls and hemodialysis patients.
* To give supplementary L-carnitine to study subjects for a duration of 5months.
* To compare the values of plasma carnitine before and after L carnitine supplementation.
* To assess the role of carnitine supplementation on biochemical and clinical parameters.

Conditions

  • Hemodialysis Complication

Interventions

DRUG

L-Carnitine 500Mg thrice daily

L-Carnitine 500mg oral thrice daily

DRUG

1g L-Carnitine IV three times a week

1g IV L-Carnitine three times a week

Sponsors & Collaborators

  • Pakistan Navy Station Shifa Hospital

    collaborator OTHER

  • Jinnah Postgraduate Medical Centre

    collaborator OTHER_GOV

  • University of Karachi

    collaborator OTHER

  • Bahria University

    lead OTHER

Principal Investigators

  • Sadia Rehman · Bahria University Health Sciences, Karachi

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-07-02
Completion
2023-07-10

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05817799 on ClinicalTrials.gov